Treatments for patients in the United States with in-stent restenosis (ISR) currently include layering or inserting additional stents, CABG, repeat balloon angioplasty, or brachytherapy, all of which themselves can put patients at risk of recurrent ISR.
An alternative treatment recently approved by the FDA is drug-coated balloons (DCBs), which, during PCI, transfer an antiproliferative drug into the vessel wall to preserve its diameter and function.
Having shown efficacy in reducing restenosis rates compared to traditional treatments, research has also shown that in some cases, DCBs can be used without additional stent placement, reducing the risks associated with stent implantation and offering another patient treatment option for difficult-to-treat cases.
Learning Objectives
After attending this series, participants will be able to:
- Discuss key data from coronary drug-coated balloon (DCB) clinical trials and their implications for clinical practice.
- Select appropriate patients for coronary DCBs.
- Plan for deployment of coronary DCBs, including step-by-step imaging guidance and lesion preparation.
- Examine in-stent restenosis (ISR) cases, including single-layer, double-layer, and stent failure.
- Explore other evidence-based applications of coronary DCBs
Target Audience
This course is suitable for:
- interventional cardiologists
- invasive non-interventional cardiologists
- interventional cardiology fellows-in-training
- catheterization laboratory nurses and technicians
Webinar 1—In-Stent Restenosis, Step-by-Step How to Treat
Wednesday, August 27, 6:00 - 7:00 PM EST
Webinar 2—Coronary DCBs in De Novo Lesions, Small Vessel, and Bifurcation: The European Experience
Saturday, September 6, 10:00 - 11:00 AM EST
Webinar 3—Bringing It All Together: Case Reviews of In-Stent Restenosis
Wednesday, September 24, 6:00 - 7:00 PM EST